Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer

Gabriella Martino, Antonino Catalano, Rita Maria Agostino, Federica Bellone, Nunziata Morabito, Carmen Giulia Lasco, Carmelo Mario Vicario, Peter Schwarz, Ulla Feldt-Rasmussen, Gabriella Martino, Antonino Catalano, Rita Maria Agostino, Federica Bellone, Nunziata Morabito, Carmen Giulia Lasco, Carmelo Mario Vicario, Peter Schwarz, Ulla Feldt-Rasmussen

Abstract

Introduction: Aromatase inhibitors (AIs) dramatically increased breast cancer (BC) survival, leading to enhanced attention to their long-term consequences on psychological functioning. Conflicting data has been examined regarding the association between AIs administration and the clinical psychological features in BC survivors (BCSs).

Purpose: As psychological symptoms often occur in such chronic diseases, our study aimed at exploring anxious and depressive symptoms and the perceived quality of life (QoL) in BCSs assessed for osteoporosis.

Methods: The total sample consisted of a clinical sample of 51 outpatient postmenopausal women, diagnosed with BC, and a control group composed of 51 healthy postmenopausal women. All recruited participants were evaluated through the clinical gold standard interview and completed the following self-rating scales: the Hamilton Anxiety Rating Scale, Beck Depression Inventory II edition, and 36-Item Short Form Health Survey, which were administered at baseline and after 6 months in BCSs in AIs treatment, compared with controls. Moreover, all participants were assessed for vitamin D status, bone mineral density (BMD) and subclinical vertebral fractures. Data regarding age, age at menopause, body mass index (BMI), smoking habits and alcohol consumption was collected.

Results: BCSs (n = 51) showed higher anxious and depressive symptoms, and lower perceived QoL vs. controls (n = 51) (p<0.05 for all). After 6 months of treatment with AIs, BCSs showed significant reduction of anxious and depressive symptoms and a significantly higher perceived QoL for both physical and mental components, vs. controls.

Conclusions: The improvement of clinical psychological features and perceived QoL was associated with AIs treatment in women being treated with, for early breast cancer. Further studies are needed to obtain a deeper comprehension of the correlation between clinical psychological and physical features in BCSs.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Clinical psychological features and comparison…
Fig 1. Clinical psychological features and comparison at baseline (Left column of each signature) and after 6 months (Right column of each signature).
Bars = mean values; Error bars = 95% CI for means; * = p

References

    1. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. The global burden of cancer 2013. JAMA Oncology. 2015. July 1;1(4):505–27. 10.1001/jamaoncol.2015.0735
    1. Schagen SB, Vardy J. Cognitive dysfunction in people with cancer. The Lancet Oncology. 2007. October 1;8(10):852–3. 10.1016/S1470-2045(07)70287-5
    1. Ahles TA, Root JC, Ryan EL. Cancer-and cancer treatment–associated cognitive change: an update on the state of the science. Journal of Clinical Oncology. 2012. October 20;30(30):3675 10.1200/JCO.2012.43.0116
    1. Ganz PA, Petersen L, Castellon SA, Bower JE, Silverman DH, Cole SW, et al. Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study. Journal of Clinical Oncology. 2014. November 1;32(31):3559 10.1200/JCO.2014.56.1662
    1. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Journal of Clinical Oncology. 1999. May 1;17(5):1474–81. 10.1200/JCO.1999.17.5.1474
    1. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005. January 1;365(9453):60–2. 10.1016/S0140-6736(04)17666-6
    1. Rocha-Cadman X, Massie MJ, Du Hamel K. Aromatase inhibitors and mood disturbances. Palliative & Supportive Care. 2012. Sep;10(3):225–7.
    1. Roberts K, Rickett K, Greer R, Woodward N. Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 2017. March 1;111:66–80. 10.1016/j.critrevonc.2017.01.010
    1. Martino G, Catalano A, Bellone F, Russo GT, Vicario CM, Lasco A, et al. As Time Goes by: Anxiety Negatively Affects the Perceived Quality of Life in Patients With Type 2 Diabetes of Long Duration. Frontiers in Psychology. 2019;10:1779 10.3389/fpsyg.2019.01779
    1. Rosenberg SM, Stanton AL, Petrie KJ, Partridge AH. Symptoms and symptom attribution among women on endocrine therapy for breast cancer. The Oncologist. 2015. June 1;20(6):598–604. 10.1634/theoncologist.2015-0007
    1. Marchini F, Caputo A, Napoli A, Balonan JT, Martino G, Nannini V, et al. Chronic illness as loss of good self: underlying mechanisms affecting diabetes adaptation. Mediterranean Journal of Clinical Psychology. 2018. December 20;6(3). 10.6092/2282-1619/2018.6.1981
    1. Settineri S, Frisone F, Merlo EM, Geraci D, Martino G. Compliance, adherence, concordance, empowerment, and self-management: five words to manifest a relational maladjustment in diabetes. Journal of Multidisciplinary Healthcare. 2019;12:299 10.2147/JMDH.S193752
    1. Martino G, Caputo A, Bellone F, Quattropani MC, Vicario C. Going Beyond the Visible in Type 2 Diabetes Mellitus: Defense Mechanisms and their Associations with Depression and Health-Related Quality of Life. Frontiers in Psychology. 2020. February; 10.3389/fpsyg.2020.00267
    1. Vicario CM, Salehinejad MA, Felmingham K, Martino G, Nitsche MA. A systematic review on the therapeutic effectiveness of non-invasive brain stimulation for the treatment of anxiety disorders. Neuroscience & Biobehavioral Reviews. 2018. December 10 10.1016/j.neubiorev.2018.12.012
    1. Martino G, Bellone F, Langher V, Caputo A, Catalano A, Quattropani MC, et al. Alexithymia and Psychological Distress Affect Perceived Quality of Life in Patients with Type 2 Diabetes Mellitus. Mediterranean Journal of Clinical Psychology. 2019. December 12;7(3).
    1. Martino G, Langher V, Cazzato V, Vicario CM. Psychological factors as determinants of medical conditions. Frontiers in psychology. 2019;10:2502 10.3389/fpsyg.2019.02502
    1. Lenzo V, Sardella A, Martino G, Quattropani MC. A systematic review of metacognitive beliefs in chronic medical conditions. Front. Psychol. 10: 2875 10.3389/fpsyg.2019.02875 2020. January 10
    1. Dell’Osso L, Stratta P, Conversano C, Massimetti E, Akiskal KK, Akiskal HS, et al. Lifetime mania is related to post-traumatic stress symptoms in high school students exposed to the 2009 L’Aquila earthquake. Comprehensive Psychiatry. 2014. February 1;55(2):357–62. 10.1016/j.comppsych.2013.08.017
    1. Dell'Osso L, Carmassi C, Rucci P, Ciapparelli A, Conversano C, Marazziti D. Complicated grief and suicidality: the impact of subthreshold mood symptoms. CNS Spectrums. 2011. Jan;16(1):1–6. 10.1017/S1092852912000090
    1. Carmassi C, Shear MK, Massimetti G, Wall M, Mauro C, Gemignani S, et al. Validation of the Italian version Inventory of Complicated Grief (ICG): A study comparing CG patients versus bipolar disorder, PTSD and healthy controls. Comprehensive Psychiatry. 2014. July 1;55(5):1322–9. 10.1016/j.comppsych.2014.03.001
    1. Piccinni A, Origlia N, Veltri A, Vizzaccaro C, Marazziti D, Catena-Dell'Osso M, et al. Plasma β-amyloid peptides levels: a pilot study in bipolar depressed patients. Journal of Affective Disorders. 2012. April 1;138(1–2):160–4. 10.1016/j.jad.2011.12.042
    1. Martino G, Sardella A, Bellone F, Lasco C, Langher V, Cazzato V, et al. Executive functions and bone health: a focus on cognitive impulsivity and bone mineral density. Mediterranean Journal of Clinical Psychology. 2019. August 1;7(2). 10.6092/2282-1619/2019.7.2167
    1. Catalano A, Sardella A, Bellone F, Lasco CG, Martino G, Morabito N. Executive functions predict fracture risk in postmenopausal women assessed for osteoporosis. Aging clinical and experimental research. 2019. Nov 26:1–7.
    1. Catalano A, Martino G, Bellone F, Papalia M, Lasco C, Basile G, et al. Neuropsychological Assessment in Elderly Men with Benign Prostatic Hyperplasia Treated with Dutasteride. Clinical drug investigation. 2019. January 31;39(1):97–102. 10.1007/s40261-018-0720-7
    1. Barberis N, Quattropani MC, Cuzzocrea F. Relationship between motivation, adherence to diet, anxiety symptoms, depression symptoms and quality of life in individuals with celiac disease. Journal of psychosomatic research. 2019. September 1;124:109787 10.1016/j.jpsychores.2019.109787
    1. Marchi L, Marzetti F, Orrù G, Lemmetti S, Miccoli M, Ciacchini R, et al. Alexithymia and psychological distress in patients with fibromyalgia and rheumatic disease. Frontiers in psychology. 2019;10 10.3389/fpsyg.2019.00010
    1. Sheikh S, Dahiya S, Ansari AH, Kumar MM. The association of quality of life between anxiety and depression in patients with chronic rheumatic heart disease. Mediterranean Journal of Clinical Psychology. 2019. August 10;7(2). 10.6092/2282-1619/2019.7.2164
    1. Castelnuovo G, Pietrabissa G, Manzoni GM, Corti S, Ceccarini M, Borrello M, et al. Chronic care management of globesity: promoting healthier lifestyles in traditional and mHealth based settings. Frontiers in Psychology. 2015. October 15;6:1557 10.3389/fpsyg.2015.01557
    1. Rahnea Nița RA., Popescu M., Ciuhu AN., et al. The relationship between anxiety, depression and sense of illness understanding in palliative cancer patients. Archives of the Balkan Medical Union. 2016. 51, 25–28.
    1. Rahnea-Nita RA, Paunica S, Motofei C, Rahnea-Nita G. Assessment of anxiety and depression in patients with advanced gynaecological cancer. Mediterranean Journal of Clinical Psychology. 2019. August 10;7(2). 10.6092/2282-1619/2019.7.2214
    1. Hermelink K, Henschel V, Untch M, Bauerfeind I, Lux MP, Munzel K. Short‐term effects of treatment‐induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study. Cancer. 2008. November 1;113(9):2431–9. 10.1002/cncr.23853
    1. Ribi K, Aldridge J, Phillips KA, Thompson A, Harvey V, Thürlimann B, et al. Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. British Journal of Cancer. 2012. May;106(10):1618–25. 10.1038/bjc.2012.156
    1. Frank JS, Vance DE, Jukkala A, Meneses KM. Attention and memory deficits in breast cancer survivors: implications for nursing practice and research. Journal of Neuroscience Nursing. 2014. October 1;46(5):274–84. 10.1097/JNN.0000000000000078
    1. Ates O, Soylu C, Babacan T, Sarici F, Kertmen N, Allen D, et al. Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors. SpringerPlus. 2016. December 1;5(1):486.
    1. Maass SW, Roorda C, Berendsen AJ, Verhaak PF, de Bock GH. The prevalence of long-term symptoms of depression and anxiety after breast cancer treatment: a systematic review. Maturitas. 2015. September 1;82(1):100 10.1016/j.maturitas.2015.04.010
    1. Bidstrup PE, Christensen J, Mertz BG, Rottmann N, Dalton SO, Johansen C. Trajectories of distress, anxiety, and depression among women with breast cancer: Looking beyond the mean. Acta Oncol. 2015. May;54(5):789–96. 10.3109/0284186X.2014.1002571
    1. Vance V, Mourtzakis M, Hanning R. Relationships Between Weight Change and Physical and Psychological Distress in Early-Stage Breast Cancer Survivors. Cancer Nurs. 2019. May-Jun;42(3):E43–E50. 10.1097/NCC.0000000000000612
    1. Henselmans I, Helgeson VS, Seltman H, de Vries J, Sanderman R, Ranchor AV. Identification and prediction of distress trajectories in the first year after a breast cancer diagnosis. Health Psychol. 2010. March;29(2):160–8. 10.1037/a0017806
    1. Kant J, Czisch A, Schott S, Siewerdt-Werner D, Birkenfeld F, Keller M. Identifying and predicting distinct distress trajectories following a breast cancer diagnosis—from treatment into early survival. J Psychosom Res. 2018. December;115:6–13. 10.1016/j.jpsychores.2018.09.012
    1. Junghaenel DU, Cohen J, Schneider S, Neerukonda AR, Broderick JE. Identification of distinct fatigue trajectories in patients with breast cancer undergoing adjuvant chemotherapy. Support Care Cancer. 2015. September;23(9):2579–87. 10.1007/s00520-015-2616-x
    1. Lam WW, Soong I, Yau TK, Wong KY, Tsang J, Yeo W, et al. The evolution of psychological distress trajectories in women diagnosed with advanced breast cancer: a longitudinal study. Psychooncology. 2013. December;22(12):2831–9. 10.1002/pon.3361
    1. Stanton AL. What happens now? Psychosocial care for cancer survivors after medical treatment completion. J Clin Oncol 2012;30:1215–1220. 10.1200/JCO.2011.39.7406
    1. Ho SS, So WK, Leung DY, Lai ET, Chan CW. Anxiety, depression and quality of life in Chinese women with breast cancer during and after treatment: a comparative evaluation. Eur J Oncol Nurs. 2013. December;17(6):877–82. 10.1016/j.ejon.2013.04.005
    1. Takei H, Ohsumi S, Shimozuma K, Takehara M, Suemasu K, Ohashi Y, et al. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04). Breast Cancer Res Treat. 2012. May;133(1):227–36. 10.1007/s10549-011-1943-y
    1. Donovan KA, Gonzalez BD, Small BJ, Andrykowski MA, Jacobsen PB. Depressive symptom trajectories during and after adjuvant treatment for breast cancer. Ann Behav Med. 2014. June;47(3):292–302. 10.1007/s12160-013-9550-2
    1. Schilder CM, Eggens PC, Seynaeve C, Linn SC, Boogerd W, Gundy CM, et al. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncologica. 2009. January 1;48(1):76–85. 10.1080/02841860802314738
    1. Catalano A, Martino G, Bellone F, Gaudio A, Lasco C, Langher V, et al. Anxiety levels predict fracture risk in postmenopausal women assessed for osteoporosis. Menopause. 2018. October 1;25(10):1110–5. 10.1097/GME.0000000000001123
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed Washington, DC: American Psychiatric Association; 2013.
    1. Rickham PP. Human experimentation. Code of ethics of the world medical association. Declaration of Helsinki. British Medical Journal. 1964. July;2(5402):177 10.1136/bmj.2.5402.177
    1. Fava GA, Tomba E, Sonino N. Clinimetrics: the science of clinical measurements. International Journal of Clinical Practice. 2012. January;66(1):11–5. 10.1111/j.1742-1241.2011.02825.x
    1. Conti C, Carrozzino D, Patierno C, Vitacolonna E, Fulcheri M. The clinical link between type D personality and diabetes. Frontiers in Psychiatry. 2016. June 21;7:113 10.3389/fpsyt.2016.00113
    1. Langher V, Caputo A, Martino G. What happened to the clinical approach to case study in psychological research? A clinical psychological analysis of scientific articles in high impact-factor journals. Mediterranean Journal of Clinical Psychology. 2017. December 30;5(3).
    1. Beck AT, Steer RA, Brown GK. Beck Depression Inventory-II. San Antonio. 1996;78(2):490–8.
    1. Hamilton MA. The assessment of anxiety states by rating. British Journal of Medical Psychology. 1959. March;32(1):50–5. 10.1111/j.2044-8341.1959.tb00467.x
    1. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care. 1992. June 1:473–83. 10.1097/00005650-199206000-00002
    1. Apolone G, Mosconi P. The Italian SF-36 Health Survey: translation, validation and norming. Journal of Clinical Epidemiology. 1998. November 1;51(11):1025–36. 10.1016/s0895-4356(98)00094-8
    1. Martino G, Catalano A, Bellone F, Sardella A, Lasco C, Caprì T, et al. Vitamin D status is associated with anxiety levels in postmenopausal women evaluated for osteoporosis. Mediterranean Journal of Clinical Psychology. 2018. April 27;6(1).
    1. Catalano A, Gaudio A, Morabito N, Basile G, Agostino RM, Xourafa A, et al. Quantitative ultrasound and DXA measurements in aromatase inhibitor-treated breast cancer women receiving denosumab. Journal of Endocrinological Investigation. 2017. August 1;40(8):851–7. 10.1007/s40618-016-0606-6
    1. Deleskog L, Laursen NØ, Nielsen BR, Schwarz P. Vertebral fracture assessment by DXA is inferior to X-ray in clinical severe osteoporosis. Osteoporosis International. 2016. July 1;27(7):2317–26. 10.1007/s00198-016-3532-8
    1. Suppli NP, Johansen C, Christensen J, Kessing LV, Kroman N, Dalton SO. Increased risk for depression after breast cancer: a nationwide population-based cohort study of associated factors in Denmark, 1998–2011. J Clin Oncol 2014;32:3831–3839. 10.1200/JCO.2013.54.0419
    1. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Journal of Clinical Oncology. 2000. November 15;18(22):3758–67. 10.1200/JCO.2000.18.22.3758
    1. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. Journal of Clinical Oncology. 2007. February 10;25(5):486–92. 10.1200/JCO.2006.08.8617
    1. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine. 2004. March 11;350(11):1081–92. 10.1056/NEJMoa040331
    1. Norbury R, Cutter WJ, Compton J, Robertson DM, Craig M, Whitehead M, et al. The neuroprotective effects of estrogen on the aging brain. Experimental Gerontology. 2003. January 1;38(1–2):109–17. 10.1016/s0531-5565(02)00166-3
    1. Cholerton B, Gleason CE, Baker LD, Asthana S. Estrogen and Alzheimer’s disease. Drugs & Aging. 2002. June 1;19(6):405–27.
    1. Cheng CM, Cohen M, Wang JI, Bondy CA. Estrogen augments glucose transporter and IGF1 expression in primate cerebral cortex. The FASEB Journal. 2001. April;15(6):907–15. 10.1096/fj.00-0398com
    1. Rossouw JE. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Jama. 2002;288:321–33. 10.1001/jama.288.3.321
    1. Shumaker SA. Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291:2947–58. 10.1001/jama.291.24.2947
    1. Hurria A, Patel SK, Mortimer J, Luu T, Somlo G, Katheria V, et al. The effect of aromatase inhibition on the cognitive function of older patients with breast cancer. Clinical Breast Cancer. 2014. April 1;14(2):132–40. 10.1016/j.clbc.2013.10.010
    1. Matthews K, Cauley J, Yaffe K, Zmuda JM. Estrogen replacement therapy and cognitive decline in older community women. Journal of the American Geriatrics Society. 1999. May;47(5):518–23. 10.1111/j.1532-5415.1999.tb02563.x
    1. Hara Y, Waters EM, McEwen BS, Morrison JH. Estrogen effects on cognitive and synaptic health over the lifecourse. Physiological Reviews. 2015. June 24;95(3):785–807. 10.1152/physrev.00036.2014
    1. Bender CM, Sereika SM, Ryan CM, Brufsky AM, Puhalla S, Berga SL. Does lifetime exposure to hormones predict pretreatment cognitive function in women before adjuvant therapy for breast cancer? Menopause. 2013. September;20(9):922–9. 10.1097/GME.0b013e3182843eff
    1. Bender CM, Merriman JD, Gentry AL, Ahrendt GM, Berga SL, Brufsky AM, et al. Patterns of change in cognitive function with anastrozole therapy. Cancer. 2015. August 1;121(15):2627–36. 10.1002/cncr.29393
    1. Merriman JD, Sereika SM, Brufsky AM, McAuliffe PF, McGuire KP, Myers JS, et al. Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer. Psychooncology. 2017. January;26(1):44–52. 10.1002/pon.4009
    1. Bender CM, Merriman JD, Sereika SM, Gentry AL, Casillo FE, Koleck TA, et al. Trajectories of Cognitive Function and Associated Phenotypic and Genotypic Factors in Breast Cancer. Oncol Nurs Forum. 2018. May 1;45(3):308–326. 10.1188/18.ONF.308-326
    1. Bender CM, Sereika SM, Brufsky AM, Ryan CM, Vogel VG, Rastogi P, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause. 2007. Nov-Dec;14(6):995–8. 10.1097/gme.0b013e318148b28b
    1. Bender CM, Merriman JD. Cancer- and treatment-related cognitive changes: what can we do now? What lies ahead? Oncology (Williston Park). 2014. September;28(9):806–8.
    1. Taira N, Iwata H, Hasegawa Y, Sakai T, Higaki K, Kihara K, et al. Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer. Breast Cancer Research and Treatment. 2014. May 1;145(1):155–64. 10.1007/s10549-014-2935-5
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica. 1983. June;67(6):361–70. 10.1111/j.1600-0447.1983.tb09716.x
    1. Vodermaier A, Millman RD. Accuracy of the Hospital Anxiety and Depression Scale as a screening tool in cancer patients: a systematic review and meta-analysis. Supportive Care in Cancer. 2011. December 1;19(12):1899 10.1007/s00520-011-1251-4
    1. Norton S, Cosco T, Doyle F, Done J, Sacker A. The Hospital Anxiety and Depression Scale: a meta confirmatory factor analysis. Journal of Psychosomatic Research. 2013. January 1;74(1):74–81. 10.1016/j.jpsychores.2012.10.010
    1. Watt T, Hegedüs L, Bjorner JB, Groenvold M, Bonnema SJ, Rasmussen ÅK, et al. Is thyroid autoimmunity per se a determinant of quality of life in patients with autoimmune hypothyroidism?. European Thyroid Journal. 2012;1(3):186–92. 10.1159/000342623
    1. Bové KB, Watt T, Vogel A, Hegedüs L, Bjoerner JB, Groenvold M, et al. Anxiety and depression are more prevalent in patients with graves' disease than in patients with nodular goitre. European Thyroid Journal. 2014;3(3):173–8. 10.1159/000365211
    1. Catalano A, Martino G, Morabito N, Scarcella C, Gaudio A, Basile G, et al. Pain in osteoporosis: from pathophysiology to therapeutic approach. Drugs & Aging. 2017. October 1;34(10):755–65.
    1. Lauriola M, Tomai M, Palma R, La Spina G, Foglia A, Panetta C, et al. Intolerance of uncertainty and anxiety-related dispositions predict pain during upper endoscopy. Frontiers in Psychology. 2019;10:1112 10.3389/fpsyg.2019.01112
    1. Fiegl S, Lahmann C, O'Rourke T, Probst T, Pieh C. Depression according to ICD-10 clinical interview vs. depression according to the Epidemiologic Studies Depression Scale to predict pain therapy outcomes. Frontiers in Psychology. 2019;10:1862 10.3389/fpsyg.2019.01862
    1. Di Giuseppe M, Ciacchini R, Micheloni T, Bertolucci I, Marchi L, Conversano C. Defense mechanisms in cancer patients: A systematic review. Journal of psychosomatic research. 2018. December 1;115:76–86. 10.1016/j.jpsychores.2018.10.016
    1. Di Giuseppe M, Ciacchini R, Piarulli A, Nepa G, Conversano C. Mindfulness dispositions and defense style as positive responses to psychological distress in oncology professionals. European Journal of Oncology Nursing. 2019. June 1;40:104–10. 10.1016/j.ejon.2019.04.003
    1. Martino G, Catalano A, Bellone F, Langher V, Lasco C, Penna A, et al. Quality of life in postmenopausal women: which role for vitamin D?. Mediterranean Journal of Clinical Psychology. 2018. August 21;6(2).
    1. Husemoen LL, Ebstrup JF, Mortensen EL, Schwarz P, Skaaby T, Thuesen BH, et al. Serum 25-hydroxyvitamin D and self-reported mental health status in adult Danes. European Journal of Clinical Nutrition. 2016. January;70(1):78 10.1038/ejcn.2015.129

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する